Amryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder Candidate
The Medical Healthcare & Products Regulatory Agency (MHRA) has granted Marketing Authorisation Approval (MAA) and Orphan Disease Designation (ODD) for Amryt’s (NASDAQ: AMYT) lead candidate Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in
